Dermatomyositis, Juvenile Clinical Trials in Hangzhou, Zhejiang

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)